Zobrazeno 1 - 10
of 98
pro vyhledávání: ''
Autor:
Theodore A. Omachi, L. Islam, Claus Bachert, Rui Zhu, Philippe Gevaert, Jonathan Corren, Monica Ligueros-Saylan, Joseph K. Han, Joaquim Mullol, Kit Wong, Ryan Owen, Derrick Kaufman, Monet Howard, Stella E. Lee
Publikováno v:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously.
Autor:
Jean-David Bouaziz, Grazyna Pulka, Jonathan I. Silverberg, Andreas Pinter, Andreas Wollenberg, Dedee F. Murrell, Christophe Piketty, Alan Clucas, Yves Poulin, Lisa Lindsey, Andrew F Alexis, Faiz Ahmad
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:173-182
Background: Nemolizumab targets the IL-31 receptor a subunit involved in atopic dermatitis (AD) pathogenesis. Objective: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD. Methods: We performed a 24-week, randomized, doub
Autor:
James G. Krueger, Usman Chaudhry, Hitokazu Esaki, Neil M.H. Graham, Maria Suprun, Jonathan I. Silverberg, Marius Ardeleanu, Xiangyu Peng, Yeriel Estrada, Hui Xu, Robert Bissonnette, Brian N. Swanson, Gianluca Pirozzi, Rick Zhang, Emma Guttman-Yassky, Mayte Suárez-Fariñas, Jennifer D. Hamilton, Alan Menter, George D. Yancopoulos, Benjamin Ungar
Publikováno v:
Journal of Allergy and Clinical Immunology. 143:155-172
Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.This placebo-controlled, double-blind trial (NCT01979016
Autor:
Qing Li, Richard F. Lockey, Giorgio Walter Canonica, Amarjot Kaur, David P. Skoner, Michael S. Blaiss, Albrecht Bufe, Hendrik Nolte, Jens Strodl Andersen, Joseph G. Ibrahim
Publikováno v:
J Allergy Clin Immunol
Background Large sample sizes are needed for sublingual immunotherapy (SLIT) trials because of inherent data variability secondary to inconsistent allergen exposure. Obtaining large sample sizes for pediatric SLIT trials is challenging, but a Bayesia
Autor:
Gary T. Ferguson, William W. Busse, Eugene R. Bleecker, J. Mark FitzGerald, Richard F. Olsson, Laura Brooks, Peter Barker, Bora study investigators, Mitchell Goldman, Ubaldo J. Martin
Publikováno v:
Journal of Allergy and Clinical Immunology. 148:266-271.e2
Background Adults and adolescents with severe asthma who completed the 48-week SIROCCO and 56-week CALIMA phase III benralizumab trials entered the safety extension study BORA (NCT02258542). The continued safety and efficacy of benralizumab in the fi
Autor:
Marshall Plaut, Amy M. Scurlock, Donald Y.M. Leung, A. Wesley Burks, Hugh A. Sampson, Robert A. Wood, Stacie M. Jones, Edwin H. Kim, Alice K. Henning, Christine B. Cho, Wendy F. Davidson, Scott H. Sicherer, M. Cecilia Berin, Peter Dawson, Robert Lindblad
Publikováno v:
J Allergy Clin Immunol
BACKGROUND: Consortium for Food Allergy Research investigators previously reported 52-week outcomes from a randomized controlled trial of peanut epicutaneous immunotherapy, observing modest and statistically significant induction of desensitization,
Publikováno v:
Journal of Allergy and Clinical Immunology. 140:431-436
Background Pharmacodynamic assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measuring 24-hour urine free cortisol (UFC) excretion. Knemometry assessing short-term lower-leg growth rate (LLGR) is a more rarely used
Autor:
Joseph L. Baumert, Lyle C. Gurrin, Gillian DunnGalvin, Giovanni A. Zurzolo, Julie A. Nordlee, Jonathan O'b Hourihane, Katrina J. Allen, Wayne G. Shreffler, Steve L. Taylor, Audrey DunnGalvin
Publikováno v:
Journal of Allergy and Clinical Immunology. 139:1583-1590
Background: Eliciting doses (EDs) of allergenic foods can be defined by the distribution of threshold doses for subjects within a specific population. The ED05 is the dose that elicits a reaction in 5% of allergic subjects. The predicted ED05 for pea
Autor:
René Zieglmayer, Friedrich Horak, Albert S. Yu, Kamal D. Puri, Guan Xing, Leanne Holes, Bart H. Steiner, Petra Zieglmayer, Patrick Lemell
Publikováno v:
Journal of Allergy and Clinical Immunology. 137:1733-1741
Phosphatidylinositol 3-kinase p110δ isoform (PI3K p110δ) activity is essential for mast cell activation, suggesting that inhibition of PI3K p110δ might be useful in treating allergic diseases.We sought to determine the effect of the PI3K p110δ-se
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
Autor:
Sam Khalil, Jonathan A. Bernstein, Karin Rosén, Marta Ferrer, Karina Raimundo, Benjamin Trzaskoma, Theodore A. Omachi, Evgeniya Antonova, James L. Zazzali, Allen P. Kaplan
Publikováno v:
Journal of Allergy and Clinical Immunology. 137(2):474-481
Background Few data are available that describe response patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab. Objective We sought to describe response patterns by using data from th